Actinium Pharmaceuticals is a clinical stage biopharmaceutical company developing innovative targeted therapies for patients with cancers lacking effective treatment options. Actinium’s proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells both safely and effectively. Actinium is currently progressing three drug candidates in clinical trials.

Capital Raised by Laidlaw Ventures: $61,000,000

Amesite is a high tech artificial intelligence software company developing a cloud-based platform for college and university courses to be cost-effectively and conveniently delivered to learners online and in hybrid online / on campus formats.  Amesite uses artificial intelligence to provide customized environments for learners, easier-to-manage interfaces for instructors, and greater accessibility for college degree seekers in the US education market and beyond.  The Company leverages existing college infrastructures, adding mass customization and cutting-edge technology to provide cost-effective, accessible, scalable and improved learning experiences to students.

Capital Raised by Laidlaw Ventures: $5,500,000

BioSig Technologies is a development stage medical device company developing a proprietary biomedical signal processing technology platform to extract information from physiologic signals. Our initial emphasis is on providing intracardiac signal information to electrophysiologists during EP studies and catheter ablation of AF and VT.

Capital Raised by Laidlaw Ventures: $24,000,000

Hoth Therapeutics is a development stage biopharmaceutical company focused on proprietary therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema. To treat indications impacting more than 32 million Americans, Hoth is working to develop and commercialize the BioLexa™ Platform, a proprietary, patented, drug compound platform developed at the University of Cincinnati. The BioLexa Platform has achieved positive results at preclinical studies conducted at the University of Miami.

Capital Raised by Laidlaw Ventures: $10,000,000